CCXI - CCXI STOCK NEWS

ChemoCentryx, Inc. (Nasdaq: CCXI) announced planned presentations for TAVNEOS® (avacopan), a selective C5a receptor inhibitor, at upcoming conferences: the American Society of Nephrology Kidney Week 2022 and the American College of Rheumatology Convergence 2022. Key presentations will focus on data from the ADVOCATE trial, highlighting renal recovery and integrated safety in patients with ANCA-associated vasculitis. The FDA has approved TAVNEOS as an adjunctive therapy for severe active ANCA-associated vasculitis, crucial for patient management alongside glucocorticoids.

ChemoCentryx announced two poster presentations for CCX559, its investigational PD-L1 checkpoint inhibitor, at the SITC 37th Annual Meeting on November 10, 2022, in Boston, MA. The presentations include results from an ongoing Phase I clinical trial in advanced solid tumors and preclinical data from animal models. CCX559 shows promise by preferentially accumulating in tumors and depleting PD-L1, enhancing T cell activation. Following the Phase I trial, ChemoCentryx plans to enter a Phase Ib/II study in early 2023 to evaluate CCX559's anti-tumor effects.

ChemoCentryx, Inc. (Nasdaq: CCXI) announced poster presentations at three medical conferences showcasing TAVNEOS® (avacopan) for ANCA-associated vasculitis. The 18th European Meeting on Complement in Human Disease will feature seven posters from August 26-29 in Bern, Switzerland. The RhAPP 2022 National Conference takes place September 8-10 in Scottsdale, Arizona, highlighting two posters related to quality of life and glucocorticoid toxicity. Concurrently, the Medscape LIVE! conference in Las Vegas will also present two posters on similar topics during the same dates.

ChemoCentryx, Inc. (CCXI) announced the cancellation of its Q2 2022 financial results conference call, originally set for August 9, 2022. This decision follows Amgen's agreement to acquire ChemoCentryx, announced on August 4, 2022. On August 8, 2022, ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.

ChemoCentryx specializes in developing oral therapeutics for inflammatory and autoimmune diseases, with TAVNEOS® (avacopan) as its leading product. The company is focused on expanding its pipeline with CCX559, a PD-L1 checkpoint inhibitor, moving into Phase Ib/II studies later in 2022.

Amgen announced its acquisition of ChemoCentryx for $52 per share in cash, totaling approximately $3.7 billion. This strategic move enhances Amgen's leadership in inflammation and nephrology, particularly with the inclusion of TAVNEOS (avacopan), a first-in-class treatment for ANCA-associated vasculitis. The acquisition is expected to close in Q4 2022, pending stockholder and regulatory approvals. TAVNEOS had $5.4 million in U.S. sales during its first full quarter. Both companies' boards have unanimously approved the deal.

ChemoCentryx, Inc. (Nasdaq: CCXI) announced that it will release its second quarter 2022 financial results after market close on August 9, 2022. An executive management conference call will take place at 5:00 p.m. ET on the same day to discuss these results. Participants can dial in using provided numbers or access a live webcast via the company’s website. ChemoCentryx specializes in developing new medications for inflammatory and autoimmune diseases, with a focus on TAVNEOS, an oral treatment for ANCA-associated vasculitis.

ChemoCentryx Appoints Jennifer L. Herron to Board

ChemoCentryx (Nasdaq: CCXI) has appointed Jennifer L. Herron as an independent director, effective June 28, 2022. With over 25 years of experience in therapeutics, Herron aims to enhance the company’s commercial efforts for TAVNEOS® (avacopan). CEO Thomas J. Schall emphasized that her alignment with the company's values will benefit patients and shareholders. Herron's previous roles include Chief Commercial Officer at ADC Therapeutics and Executive Vice President at Immunogen, contributing to her expertise in drug commercialization.

ChemoCentryx (Nasdaq: CCXI) announced positive safety results for CCX559, an orally administered PD-L1 checkpoint inhibitor, during the ASCO 2022 meeting. The ongoing Phase I study showed no dose-limiting toxicities and supportive evidence of immune activation. Of the first 13 patients treated, 10 had previously received multiple therapies. The study's primary goals include evaluating safety and determining dosing for the upcoming Phase Ib/II trials.

CCX559 demonstrated pharmacological activity in early tests, with plans for further data presentations and potential anti-tumor effects trials later in 2022.

ChemoCentryx, Inc. (Nasdaq: CCXI) announced upcoming presentations at key medical conferences in June, showcasing TAVNEOS® (avacopan) for ANCA-associated vasculitis and CCX559, a PD-L1 inhibitor for immuno-oncology. Significant presentations include the Phase 3 ADVOCATE study results at the EULAR conference and ongoing studies of CCX559 at ASCO. TAVNEOS is FDA-approved for treating severe ANCA-associated vasculitis but has safety warnings tied to hepatotoxicity and serious infections.